What are the precautions for taking Venekra?

Venetoclax is a BCL-2 inhibitor that was originally approved by the U.S. Food and Drug Administration in 2016 4 months . Veneclat is used to treat chronic lymphocytic leukemia (CLL)) and certain types of small lymphocytic lymphoma. CLLis the most common form of leukemia diagnosed in Western countries. Venecoclax was developed by reverse engineering the BCL-2 protein family of inhibitors navitoclax. Venetoclax is approximately 10 times more potent than navitoclax in inducing apoptosis in CLL cells. A new indication was approved in 2018 for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia Cellular lymphoma (SLL), with or without 17p deletion, who have received at least one prior treatment label.

1.Tumor lysis syndrome. Tumor lysis syndrome, sometimes fatal or leading to kidney failure requiring dialysis. The risk is generally greatest when first starting the drug, during dose escalations, and when patients with CLL or SLLrestart treatment after an interruption; laboratory abnormalities may occur 6-8 hours after the first dose or after each dose increase and require immediate medical attention. Assess patients for risk of tumor lysis syndrome (i.e., tumor burden, blood chemistry) and correct any abnormalities before initiating treatment and during dose escalation. Establish appropriate measures (eg, prophylactic antihyperlipidemic therapy and adequate hydration) to minimize risk; as overall risk increases, more intensive medical management (ie, intravenous hydration, frequent monitoring, hospitalization) may be necessary. If tumor lysis syndrome occurs, treatment may need to be temporarily interrupted and once treatment is resumed, patients with CLL/SLL may need to reduce their dose.

2.Neutropenia. Grade 3 or 4 neutropenia usually occurs after receivingVeneclIn patients receiving monotherapy or combination therapy. Baseline neutrophil counts worsened in ≥95% of patients with AML who received venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine. Neutropenia may recur in subsequent cycles. Monitor complete blood counts regularly during treatment. If hematologic toxicity occurs, temporary interruption of treatment or dose adjustment may be necessary. Consider supportive treatment with hematopoietic growth factors (such as G-CSF) and anti-infective drugs.

3.Infectious complications. Reported fatal and serious infections (eg, pneumonia, sepsis). Monitor for signs of infection and initiate appropriate treatment immediately. If a Grade 3 or Grade 4 infection occurs, temporarily discontinue treatment until the infection resolves; a dose reduction may be necessary.

4.Immunization. The safety and effectiveness of immunization with live-attenuated vaccines during or after treatment with veneclasehas not been established and the immune response to the vaccine may be reduced. Avoid immunization with live attenuated vaccines before, during, and after treatment untilBcell counts have recovered.

5.Fetus/Neonatal morbidity and mortality. May cause fetal harm. Avoid becoming pregnant during treatment. Before starting treatment, a pregnancy test should be performed on women of childbearing potential. Such women should use effective contraceptive measures during treatment and for ≥30 days after stopping treatment. If used during pregnancy or if the patient becomes pregnant, inform of the potential fetal hazard. The retail price of generic venetoclax100mg120 tablets ranges from 2 to 6 more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.

xa0